NovaBridge Biosciences (NBP) research
NovaBridge Biosciences- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.35
- As of
NovaBridge Biosciences (NBP): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-08.
As of . Source: SEC EDGAR filings for NBP. Method and limitations.
Share the NBP intelligence card
See the full NBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NBP on one page. Preview it with sample data, then open it live with a free account.
Preview the NBP dossierActive signals for NBP
- highCONSENSUS_BUY
4 tracked funds increased NBP this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased NBP this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +178% to NBP (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1477% to NBP (2026Q2)
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in NBP
FREE, NO ACCOUNT
Every signal on NBP, as it fires
You are seeing 5 of 12 signals recorded on NBP since 2026-06-09.
The five above landed across 2 days. The other 7 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NBP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 44975P103 · 2026Q2 | $1.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 44975P103 · 2026Q2 | $1.5M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 44975P103 · 2026Q2 | $1.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NBP
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
NBP against its peers
NBP's operating margin of -14916.0% ranks in the 5th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | NBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 632000 USD | 25.6M USD | 14 | 10 |
| Operating margin | -14916.0% | -326.6% | 5 | 9 |
| Net margin | -7321.0% | -140.8% | 5 | 9 |
| Return on equity | -20.0% | -60.9% | 82 | 18 |
Peers (20): NERV, TARA, VYGR, MENS, MOLN, ABOS, ALXO, AVXL, HUMA, CMPX, DTIL, KRRO, MDWD, CLLS, ORGO, PYXS, CHRS, CNTN, PEPG, MSLE. Left out: TNXP (no annual filing), OTLK (no annual filing), RNA (no annual filing), TLSA (period gap), BETRF (period gap). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NBP: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NBP signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NBPand get the insider, 13F, options, and confluence read in one view.